[Drug therapy of Parkinson disease and parkinson disease-like symptoms].
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001142:Aromatic-L-Amino-Acid Decarboxylases / Q000378:metabolism; D001712:Biperiden / Q000627:therapeutic use; D001921:Brain / Q000378:metabolism; D002394:Catechol O-Methyltransferase / Q000378:metabolism; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D066298:In Vitro Techniques; D051379:Mice; D008995:Monoamine Oxidase / Q000378:metabolism; D010095:Oxotremorine / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy*; D051381:Rats; D011954:Receptors, Dopamine / Q000378:metabolism; D012110:Reserpine / Q000009:adverse effects; D014282:Trihexyphenidyl / Q000627:therapeutic use
D011954:Receptors, Dopamine; D001712:Biperiden; D010095:Oxotremorine; D014282:Trihexyphenidyl; D012110:Reserpine; D008995:Monoamine Oxidase; D002394:Catechol O-Methyltransferase; D001142:Aromatic-L-Amino-Acid Decarboxylases; D000262:Adenylyl Cyclases; D004298:Dopamine
Pharmako-Therapie des Morbus Parkinson und Parkinson-ähnlicher Symptome.